MX2020004537A - Moduladores de la vía integrada del estrés. - Google Patents
Moduladores de la vía integrada del estrés.Info
- Publication number
- MX2020004537A MX2020004537A MX2020004537A MX2020004537A MX2020004537A MX 2020004537 A MX2020004537 A MX 2020004537A MX 2020004537 A MX2020004537 A MX 2020004537A MX 2020004537 A MX2020004537 A MX 2020004537A MX 2020004537 A MX2020004537 A MX 2020004537A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- integrated stress
- stress pathway
- integrated
- pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580805P | 2017-11-02 | 2017-11-02 | |
| US201862643067P | 2018-03-14 | 2018-03-14 | |
| PCT/US2018/058960 WO2019090078A1 (en) | 2017-11-02 | 2018-11-02 | Modulators of the integrated stress pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004537A true MX2020004537A (es) | 2020-10-05 |
Family
ID=64572457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004537A MX2020004537A (es) | 2017-11-02 | 2018-11-02 | Moduladores de la vía integrada del estrés. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200361881A1 (https=) |
| EP (1) | EP3704098B1 (https=) |
| JP (1) | JP7184889B2 (https=) |
| CN (1) | CN112154142B (https=) |
| AU (1) | AU2018360847B2 (https=) |
| BR (1) | BR112020008827A2 (https=) |
| CA (1) | CA3080808A1 (https=) |
| MX (1) | MX2020004537A (https=) |
| WO (1) | WO2019090078A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2019090088A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| AU2019282253A1 (en) | 2018-06-05 | 2020-11-26 | Altos Labs, Inc. | Inhibitors of integrated stress response pathway |
| TW202545902A (zh) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3959198A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| WO2020252207A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| JP7699595B2 (ja) | 2020-01-28 | 2025-06-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| CN115190813B (zh) | 2020-03-11 | 2024-10-15 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| KR20230023663A (ko) | 2020-05-21 | 2023-02-17 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 |
| RS66455B1 (sr) | 2020-10-22 | 2025-02-28 | Evotec Int Gmbh | Modulatori puta integrisanog odgovora na stres |
| EP4232447A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4232153A1 (en) | 2020-10-22 | 2023-08-30 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CN113979963B (zh) * | 2021-12-24 | 2022-03-11 | 凯思凯旭(上海)医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| WO2025259779A1 (en) * | 2024-06-12 | 2025-12-18 | Insmed Incorporated | Uses of certain carboxamides as dpp1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CA2904794C (en) * | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| US20160318856A1 (en) * | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
-
2018
- 2018-11-02 CA CA3080808A patent/CA3080808A1/en active Pending
- 2018-11-02 AU AU2018360847A patent/AU2018360847B2/en active Active
- 2018-11-02 EP EP18812423.4A patent/EP3704098B1/en active Active
- 2018-11-02 BR BR112020008827-7A patent/BR112020008827A2/pt not_active IP Right Cessation
- 2018-11-02 JP JP2020524769A patent/JP7184889B2/ja active Active
- 2018-11-02 MX MX2020004537A patent/MX2020004537A/es unknown
- 2018-11-02 CN CN201880085210.1A patent/CN112154142B/zh active Active
- 2018-11-02 WO PCT/US2018/058960 patent/WO2019090078A1/en not_active Ceased
- 2018-11-02 US US16/761,392 patent/US20200361881A1/en not_active Abandoned
-
2022
- 2022-06-14 US US17/806,905 patent/US20230144871A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/647,747 patent/US20250115563A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021501779A (ja) | 2021-01-21 |
| CA3080808A1 (en) | 2019-05-09 |
| BR112020008827A2 (pt) | 2020-10-20 |
| CN112154142B (zh) | 2023-11-21 |
| EP3704098A1 (en) | 2020-09-09 |
| AU2018360847A1 (en) | 2020-06-11 |
| US20250115563A1 (en) | 2025-04-10 |
| JP7184889B2 (ja) | 2022-12-06 |
| CN112154142A (zh) | 2020-12-29 |
| AU2018360847B2 (en) | 2023-07-27 |
| US20200361881A1 (en) | 2020-11-19 |
| EP3704098B1 (en) | 2024-01-24 |
| US20230144871A1 (en) | 2023-05-11 |
| WO2019090078A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020006248A2 (es) | Moduladores de la vía de estrés integrada | |
| ECSP20027553A (es) | Moduladores de la vía de estrés integrada | |
| MX2020004557A (es) | Moduladores de la vía de estrés integrada. | |
| ECSP21086429A (es) | Moduladores de la vía integrada del estrés | |
| MX2020004537A (es) | Moduladores de la vía integrada del estrés. | |
| ECSP21032861A (es) | Moduladores de profármacos de la vía de estrés integrada | |
| MX2020004558A (es) | Moduladores de la vía de estrés integrada. | |
| ECSP18089579A (es) | Moduladores de la vía de estrés integrada | |
| MX2020004556A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004538A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004519A (es) | Moduladores de la vía de estrés integrada. | |
| MX2020004534A (es) | Moduladores de la vía integrada del estrés. | |
| UY37230A (es) | Moduladores de la vía de estrés integrada | |
| UY37231A (es) | Moduladores de la vía de estrés integrada | |
| UY37229A (es) | Moduladores de la vía de estrés integrada | |
| DOP2021000151A (es) | Moduladores de la vía de estrés integrada | |
| CR20200213A (es) | Moduladores de la vía de estrés integrada |